论文部分内容阅读
摘要目的使用一种新C型臂成像平台,在保持诊断影像质量前提下,量化减少肝癌病人经动脉化学栓塞(TACE)时的辐射。方法该前瞻性研究符合HIPAA并经伦理审查委员会(IRB)批准。在双臂试验中,连续78例原发或继发肝癌病人在升级整合优化采集参数和提高实时图像处理算法前后,采用一种C型臂成像平台行TACE。记录剂量面积乘积(DAP)和每个数字透视(DF)、数字减影血管造影(DSA)和锥形束CT(CBCT)的曝光时间。DSA影像质量由2名阅片者在4-等级量表上双盲、独立评估。结果 2组队列在病人特征和肿瘤负荷方面无显著差异。和旧平台相比,新系统显著减少
Abstract Objective To quantify the radiation of transcatheter arterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC) while maintaining the quality of diagnostic imaging using a new C-arm imaging platform. Methods This prospective study was HIPAA approved by the Ethics Review Board (IRB). In a two-arm trial, TACE was performed using a C-arm imaging platform in 78 consecutive patients with primary or secondary liver cancer before and after upgrading and optimizing acquisition parameters and improving real-time image processing algorithms. The dose area product (DAP) and exposure time for each digital fluoroscopy (DF), digital subtraction angiography (DSA), and cone beam CT (CBCT) were recorded. DSA image quality was double-blind, independently assessed by 2 readers on a 4-scale scale. Results There were no significant differences in patient characteristics and tumor burden between the two cohorts. Compared with the old platform, the new system significantly reduced